Abcam’s (ABC) Hold Rating Reaffirmed at Peel Hunt
Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Abcam from GBX 946 ($12.59) to GBX 1,011 ($13.46) and gave the stock a neutral rating in a report on Thursday, March 15th. Berenberg Bank lowered shares of Abcam to a hold rating and decreased their price target for the stock from GBX 1,240 ($16.51) to GBX 1,230 ($16.38) in a research report on Monday, March 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The company presently has an average rating of Hold and an average target price of GBX 1,135.25 ($15.11).
Abcam traded up GBX 20 ($0.27), hitting GBX 1,352 ($18.00), during trading on Thursday, according to MarketBeat. The stock had a trading volume of 849,072 shares, compared to its average volume of 497,233. Abcam has a 12 month low of GBX 9.73 ($0.13) and a 12 month high of GBX 1,290 ($17.17).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.